Dr Jasper De Boer’s Group publishes the targets identified with NPOT®
Strasbourg – November 2017
Dr Jasper De Boer’s group at University College London (UCL), is dedicated to drug discovery, with the aim to improve treatments and outcomes for children with Acute Myeloid Leukemia (AML). As part of his research, he established that the Mebendazole, a drug used to treat infections caused by worms, could also inhibit the transcription factor c-MYB, which is known for initiating MLL-rearranged AML. In order to understand and characterize this unintended side effect of the Mebendazole in the leukemia indication, he initiated a target identification project together with Inoviem Scientific in December 2015.
Inoviem Scientific is happy to announce that Dr Jasper De Boer’s Group published in Leukemia (IF=11.07) the validation of the targets identified with the NPOT® technology. Indeed, thanks to Inoviem Scientific’s proprietary technology, the heat shock protein 70 (HSP70) was identified as a target of the Mebendazole in THP1 cells. Dr Jasper De Boer’s Group then demonstrated the role of the HSP70 chaperon system in the c-MYB degradation via the proteasome.
Please read the publication “Targeting acute myeloid leukemia by drug-induced c-MYB degradation” for more information. We are convinced that this success story could be reproduced with your project ! Don’t hesitate to contact us.
Citation: V Walf-Vorderwu¨ lbecke, K Pearce, T Brooks, M Hubank, M M van den Heuvel-Eibrink, C M Zwaan, S Adams, D Edwards, J Bartram, S Samarasinghe, P Ancliff, A Khwaja, N Goulden, G Williams, J de Boer, O Williams, Targeting acute myeloid leukemia by drug-induced c-MYB degradation, Leukemia accepted article preview 1 November 2017; doi: 10.1038/leu.2017.317.